Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WGb-0302
- Development stage
- Phase 1
- Lead developer
- Sichuan University
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intramuscular
01
Overview
WGb-0302 is an experimental mRNA-based therapeutic drug developed by Sichuan University for the treatment of recurrent and refractory hematological malignancies, primarily multiple myeloma. The therapy utilizes lipid nanoparticle (LNP) technology to encapsulate and deliver mRNA encoding proteins that target B-cell maturation antigen (BCMA), a protein highly expressed on the surface of malignant plasma cells. By leveraging the LNP-mRNA platform, WGb-0302 aims to induce the endogenous production of anti-BCMA proteins to selectively target and eliminate myeloma cells. It is currently undergoing early-phase clinical evaluation to assess its safety, tolerability, and preliminary therapeutic efficacy in patients who have failed standard treatments such as proteasome inhibitors, immunomodulators, and CD38 monoclonal antibodies.
- Other names
- WGb-0302 injectionWGb0302 injectionWGb 0302 injection
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on WGb-0302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WGb-0302.